C-LINK SQ(01463.HK)斥逾4.7億元購內地互聯網醫院及實體門診業務 發行代價股份支付
C-LINK SQ(01463.HK)公布,其直接全資附屬Core Squared向樂羨及鄒程收購盛濟投資共100%股權,代價共約4.74億元,分別以向鄒程旗下SJ Capital Investment及樂羨旗下SJ Venture Management發行2.85億及1.9億股代價股份支付,佔公司擴大後股本約16.5%,每股發行價1元,與昨日(28日)收市價相同。
盛濟投資旗下綜合聯屬實體的主要業務涉及在內地提供互聯網醫院及實體門診服務。
公司認為,由於醫療保健成本持續上升,盛濟互聯網醫院作為一家數字醫療保健供應商,能夠通過其平台提供更實惠的醫療保健服務,包括但不限於疾病診斷、在線處方、藥品配送及健康管理。因此,收購事項為集團與目標集團帶來協同效應,實現技術、保險及醫療保健服務的合作模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.